



ORIGINAL ARTICLE

Ultra-short celiac disease exhibits differential genetic and immunophenotypic features compared to conventional celiac disease



Pilar Mata-Romero^{a,*}, Daniel Martín-Holgado^a, Hal C. Ferreira-Nossa^a, Pedro L. González-Cordero^a, Ana Izquierdo-Martín^b, Patricia Barros-García^b, Nuria Fernandez-Gonzalez^c, Luis Fernández-Pereira^d, Carmen Cámara-Hijón^d, Javier Molina-Infante^{a,e}

^a Department of Gastroenterology, Hospital Universitario de Cáceres, Cáceres, Spain

^b Department of Pediatrics, Hospital San Pedro de Alcantara, Cáceres, Spain

^c Department of Pathology, Hospital Universitario de Cáceres, Cáceres, Spain

^d Department of Immunology, Hospital San Pedro de Alcantara, Cáceres, Spain

^e Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain

Received 23 October 2021; accepted 21 March 2022

Available online 28 April 2022

KEYWORDS

Coeliac disease;
Ultra-short;
Flow cytometry

Abstract

Background: Ultra-short coeliac disease (USCD) is a novel celiac disease (CD) subtype limited to the duodenal bulb (D1). HLA haplotypes and flow cytometry have not been assessed yet.

Aims: To compare genetic, clinical, serologic, histopathologic and immunophenotypic parameters between USCD and conventional celiac disease (CCD) patients.

Methods: Prospective single-center study in children and adult patients undergoing duodenal biopsies on a gluten-containing diet. Biopsies for histology and flow cytometry were taken separately from D1 and distal duodenum. Biopsies in seronegative patients with celiac lymphogram were repeated after 2 years on a gluten-free diet.

Results: Among 505 included patients, 127 were diagnosed with CD, of whom 7 (5.5%) showed USCD. HLA-DQ2 was significantly less common in USCD compared to CCD (71% vs. 95%, p 0.003).

Abbreviations: CCD, conventional celiac disease; CD, celiac disease; D1, duodenal bulb; EMA, endomysial antibodies; GFD, gluten-free diet; HLA, human leukocyte antigen; IELs, intraepithelial lymphocytes; NK, natural killer; TCR $\gamma\delta$ +, T-cell receptor gammadelta positive; tTG-IgA, tissue transglutaminase antibodies; USCD, ultra-short celiac disease.

* Corresponding author.

E-mail address: pmataromero@gmail.com (P. Mata-Romero).

<https://doi.org/10.1016/j.gastrohep.2022.03.011>

0210-5705/© 2022 Elsevier España, S.L.U. All rights reserved.

PALABRAS CLAVE

Enfermedad celiaca;
Enfermedad celiaca
ultracorta;
Citometría de flujo

Likewise, USCD patients showed more frequent non-significant seronegativity (28% vs. 8%, p 0.07) and significantly lower titrations (7–15 IU/ml) of tissue transglutaminase antibodies (tTG-IgA) (60% vs. 13%, $p < 0.001$). Biopsies from D1 revealed significant less NK cells down-expression in USCD patients (1.4 vs. 5, p 0.04).

Conclusions: Up to 5.5% of CD patients showed USCD. A lower frequency of HLA-DQ2, along with less serum tTG-IgA titration and duodenal NK cell suppression, were differential features of USCD.

© 2022 Elsevier España, S.L.U. All rights reserved.

La enfermedad celiaca ultra corta presenta una expresión genética e inmunológica distinta a la de la enfermedad celiaca convencional

Resumen

Antecedentes: La enfermedad celiaca ultracorta (ECUC) es un nuevo fenotipo de la enfermedad celiaca, que afecta exclusivamente al bulbo duodenal (D1), cuyas características genéticas e inmunológicas no han sido descritas.

Objetivos: Comparar las características genéticas, clínicas, serológicas, histológicas e inmunológicas entre ECUC y enfermedad celiaca convencional (ECC).

Métodos: Estudio prospectivo, unicéntrico, en el que se realizaron biopsias duodenales a pacientes adultos y pediátricos que seguían una dieta con gluten. Se realizó análisis histológico y por citometría de flujo por separado de duodeno distal y D1. En pacientes seronegativos con histología o linfograma concordante con EC, se repitió la biopsia tras 2 años con dieta sin gluten.

Resultados: Se incluyeron 505 pacientes, siendo diagnosticados 127 de enfermedad celiaca, de los cuales 7 (5,5%) tenían ECUC. Los pacientes con ECUC expresaron el haplotipo DQ2 con menor frecuencia que en la ECC (71% vs. 95%, p 0,003) y presentaron mayor seronegatividad (28% vs. 8%, p 0,07) y, de manera significativa, titulaciones bajas de anticuerpos antitransglutaminasa (7-15 IU/ml) (60% vs. 13%, $p < 0,001$). Comparado con la ECC, la citometría de flujo en las biopsias bulbares reveló una reducción atenuada significativa de células NK (1,4 vs. 5, p 0,04) en pacientes con ECUC.

Conclusiones: Un 5,5% de los pacientes celíacos presentaron ECUC. Comparada con la ECC, las características diferenciales de la ECUC son menor expresión de HLA-DQ2, títulos más bajos de anticuerpos antitransglutaminasa y menor supresión de células NK a nivel bulbar.

© 2022 Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Celiac disease (CD) is defined as an immune-mediated enteropathy, elicited by gluten and related prolamines in genetically susceptible individuals, affecting approximately 1% of the general population.¹ Despite increased awareness, CD remains underdiagnosed due to a variety of reasons, including heterogeneous clinical presentation, mild or negative laboratory abnormalities and discordance among clinic, serologic and histologic findings. Revealing the submerged CD iceberg, therefore, requires high clinic suspicion while maximizing available diagnostic tests.

In this regard, a novel CD subtype coined ultra-short celiac disease (USCD) has been recently described in both children and adults.^{2,3} USCD refers to an enteropathy limited to the duodenal bulb (D1), which may represent early CD with a mild clinical, serological and histological phenotype. Immunophenotypically, CD is characterized by an increase in the absolute numbers of T-cell receptor gamma-madelta positive (TCR $\gamma\delta$ +) intraepithelial lymphocytes (IELs)

up to 25% of all IELs, compared to 4% in healthy controls.⁴ Another abnormality observed in CD is a decrease in a subset of CD3-IELs with natural killer (NK) function, which become almost undetectable in active celiac disease.⁵ Two recent studies have demonstrated a high diagnostic accuracy of this celiac lymphogram for the diagnosis of CD, even in patients with seronegative villous atrophy.^{6,7} In a recent meta-analysis, this lymphogram pattern has proven to be useful in cases where the diagnosis of CD is not straightforward⁸ and, if available, it is recommended in current updated guidelines.^{1,9} This diagnostic tool has not been assessed in USCD patients yet. Differences in genetic characterization (human leukocyte antigen (HLA) haplotypes) between CD and USCD patients have not been evaluated either.

The present study aims to characterize baseline genetic, clinical, serological, histological and immunophenotypical changes in USCD patients, compared to those observed in patients diagnosed with conventional CD (CCD) and non-celiac controls.

Patients and methods

Study population

All pediatric and adult patients, without a previous diagnosis of CD, undergoing a clinically indicated upper endoscopy with duodenal biopsies at Hospital San Pedro de Alcantara, Caceres, Spain (between February 2015 and February 2018), were prospectively recruited. Patients included those with suspected CD due to positive serology, but also general and open-access referrals for anemia or any upper gastrointestinal symptom. All patients were on a gluten-containing diet at baseline endoscopy. In case of doubtful results and/or suspicion of gluten restriction, patients were re-scoped after an 8-week gluten challenge, with a daily consumption of a minimum of 12 g of gluten per day. Patients in which CD was ruled out by means of histology and flow cytometry were considered as the control population. The investigations were conducted according to the principles expressed in the Declaration of Helsinki. Approval from the Institutional Review Board was obtained. All patients signed a specific informed consent for the study before enrollment.

Demographic data

Age, gender, family history of CD, gastrointestinal and extraintestinal symptoms, along with laboratory parameters, including, were systematically collected.

CD antibodies and HLA haplotypes

Blood samples for serology, including IgA and both anti-tissue transglutaminase (tTG-IgA), were extracted from all included patients. If positive tTG-IgA (>7 IU/mL) or high suspicion of seronegative CD, endomysial antibodies (EMA) were obtained. In case of IgA deficiency, tTG and EMA IgG were requested. tTG-IgA were assessed via fluorescence enzyme immunoassay (Thermo Scientific) using ELIATM Gliadin^{DP} IgA and IgG reagent (synthetic deaminated gliadin peptide), ELIATM Celikey IgA and IgG (recombinant human tissue transglutaminase). EMAs antibodies were detected via staining of rhesus monkey esophagus substrate by indirect immunofluorescence assay (Menarini Diagnostics). Additional blood samples for HLA haplotypes were obtained in all CCD/USCD, as well as in some patients in the control group with high clinical suspicion of CD. HLA haplotypes DQ2 and DQ8 were determined by SSO (Kit LIFECODES HLA, Luminex Longwood).

Endoscopy and histology

All patients underwent upper gastrointestinal endoscopy under endoscopist-directed propofol sedation. According to the study protocol, four biopsies were taken from distal duodenum and two from D1 for histopathological analysis. Each of the biopsy specimens was graded according to the modified Marsh criteria, to identify the presence and severity of villous atrophy. The Marsh criteria were applied consistently between the bulb and distal duodenum. All biopsies from CCD and USCD patients were carefully reviewed by a

senior gastrointestinal pathologist (NF-G) with expertise on CD, who was blinded for clinical and serological data.

Flow cytometry analysis

Two additional biopsy samples from D1 and two more from distal duodenum were obtained during endoscopy for flow cytometry analysis. Samples were placed in saline solution to avoid spontaneous de-epithelization and immediately transferred to the laboratory in the department of Immunology.

Epithelial and intraepithelial cells were isolated from intestinal biopsies as described elsewhere.¹⁰ Both TCR $\gamma\delta$ ⁺ and NK cells were selected, which were measured as CD45+CD103+TCR $\gamma\delta$ ⁺ and CD45+CD3[−]CD103⁺, respectively, over the total CD45+CD103⁺ cells. The results were assessed by two immunologists (LF-P, CC-H), who were blinded to the results of serology and histology. The celiac lymphogram was defined as an increase in TCR $\gamma\delta$ ⁺ cells $\geq 10\%$ plus a concomitant decrease in NK cells $\leq 10\%$.⁷

Diagnosis of CCD and USCD

A diagnosis of CD was made upon the combination of compatible symptoms, serology and histology/flow cytometry findings.¹ CCD patients showed pathological and ultrastructural changes at both D1 and distal duodenum, whereas these changes were confined to D1 in patients with USCD.

In cases of symptomatic seronegative patients with histology/flow cytometry consistent with CD/USCD, HLA haplotypes were performed. If positive, a thorough re-examination looking for alternative causes of histologic findings (including *H. pylori* infection, parasites, medications, small intestinal bacterial overgrowth, inflammatory bowel disease), was performed.¹² After these potential causes were ruled out, patients were given a diagnosis of possible CD/USCD and were re-scoped after a minimum of 2 years on a strict gluten-free diet (GFD), with the same biopsy protocol. Subjective symptom improvement, normalization of histological findings (Marsh 0) and NK cell count in flow cytometry on a GFD, were required for a definitive CD/USCD diagnosis.^{11–13}

Statistical analysis

Demographic characteristics of CD and USCD patients and non-celiac controls were compared using the Chi-Square test (categorical data) and the *t*-test (quantitative data). Median and 25–75th percentiles were used to express the densities of IELs in celiac and non-celiac patients. Significance was set at $p < 0.05$. IBM SPSS Statistics for Windows (Version 22.0. Armonk, NY: IBM Corp) was used for all statistical analyses.

Results

Flow chart of patients and demographics

A total of 505 patients, of whom 95 (19%) were children, were included. CD was finally diagnosed in 25% of the




Figure 1 Flow chart of patients with diagnostic work-up during the study.

evaluated population (127 patients), of whom 7 (5.5%) suffered from USCD (3.8% in children, 6.6% in adults). The flow chart of patients during the study is shown in Fig. 1. Among controls ($n = 378$), 85% ($n = 321$) exhibited normal duodenal biopsies (Marsh 0) with normal flow cytometry features. The remaining 57 patients showed non-specific histologic findings (Marsh I–II), with normal celiac lymphogram, negative antibodies and/or negative HLA haplotypes in all cases.

Demographic characteristics, clinical manifestations, and laboratory findings in all evaluated populations are displayed in Table 1. Compared to CCD, USCD patients showed a significant higher frequency of dyspepsia (42% vs. 9%, $p = 0.006$). Likewise, USCD exhibited fewer bowel habit changes, less hypoferritinemia, and more common family history of CD. No statistical differences were observed when comparing these parameters, likely due to small sample size in USCD patients.

HLA haplotypes

HLADQ2 was significantly less common in USCD compared to CCD (71% vs. 95%, $p = 0.003$). HLADQ2 was present in 42% of control population. There were no differences in regards to HLADQ8 haplotype (14% vs. 15%, $p = 0.7$). Only one patient among 7 USCD (14%) did not express neither DQ2 nor DQ8 haplotypes, whereas all patients in the CCD group showed DQ2, DQ8 or both haplotypes.

CD antibodies

Seronegativity ($tTG-IgA < 7$ IU/mL) was borderline significantly more common in patients with USCD than in those with CCD (28% vs. 8%, $p = 0.07$). No seronegative patient in both groups exhibited positive anti-EMA. In patients with positive serology (anti- $tTG \geq 7$ IU/mL), baseline antibody titration for $tTG-IgA$ in CCD and USCD patients is shown in Fig. 2. Low




Figure 2 Baseline titration of $tTG-IgA$ antibodies compared between USCD and CCD patients.

titration of $tTG-IgA$ between 7 and 15 IU was significantly more frequent in USCD patients [60% vs. 12%, $p < 0.001$].

Histology

Prior to the present study, a total of 22 patients (4%) had normal duodenal biopsies (not including duodenal bulb), taken in the context of high suspicion of CD. Noteworthy, 5 out of 7 of USCD (70%) belonged into this group, of whom 3 (42%) were diagnosed with potential CD based on symptoms and positive serology, but normal histological findings in distal duodenum biopsies. Histological results in USCD and CCD patients, both in D1 and distal duodenum, are exhibited in Table 2. The presence of villous atrophy (Marsh 3) was similar in both groups (86% D1 in USCD vs. 87% distal duodenum in CCD). Of note, villous atrophy in D1 could only be documented in 60% of CCD patients. Two patients in the control population were diagnosed with seronegative villous atrophy and non-celiac flow cytometry. Both patients were finally

Table 1 Baseline demographic, clinic and laboratory findings in the study population.

	Controls (n = 378)	p	CCD (n = 120)	USCD (n = 7)	p
Demographics					
Age, yrs Mean (range)	41 (1–85)	<0.001	25 (1–73)	19 (4–32)	0.4
Children < 14 yrs	41 (11%)	<0.001	50 (42%)	2 (28%)	0.4
Female gender	268 (71%)	0.1	74 (58%)	4 (50%)	0.8
Familial history of CD	26 (7%)	<0.001	33 (28%)	4 (57%)	0.1
Concomitant autoimmune diseases	41 (11%)	0.1	21 (18%)	1 (14%)	0.8
Clinical manifestations					
Alternating bowel habit	75 (20%)	0.3	22 (18%)	0	0.2
Diarrhea	143 (38%)	0.4	44 (37%)	1 (14%)	0.2
Abdominal pain	234 (62%)	0.04	59 (49%)	4 (50%)	0.7
Bloating	120 (32%)	0.06	26 (22%)	1 (14%)	0.6
Dyspepsia	124 (33%)	<0.001	11 (9%)	3 (42%)	0.006
Heartburn	53 (14%)	0.05	8 (7%)	0	0.4
Nausea, vomiting	94 (25%)	0.08	21 (17%)	0	0.2
Asthenia	34 (9%)	0.1	5 (4%)	0	0.6
Laboratory findings					
Anemia	124 (33%)	0.9	40 (33%)	2 (28%)	0.8
Hypoferritinemia	87 (23%)	0.002	48 (37%)	1 (14%)	0.2

Table 2 Histological differences in separated duodenal biopsies between evaluated populations.

	Controls (n = 374)	p*	CCD (n = 120)	USCD (n = 7)	p**
D1					
Villous atrophy (Marsh 3)	2 (0.5%)	<0.001	72 (60%)	6 (86%)	0.5
Non-specific findings	183 (48%)	<0.001	32 (40%)	1 (14%)	0.9
Marsh 0	191 (51.5%)	<0.001	0	0	–
Distal duodenum					
Villous atrophy (Marsh 3)	2 (0.5%)	<0.001	105 (87%)	0	<0.001
Non-specific findings	104 (27%)	<0.001	15 (13%)	7 (100%)	<0.001
Marsh 0	268 (71%)	<0.001	0	0	–

* Comparison between control and CD populations.

** Only when comparing CCD and USCD patients.

diagnosed with *Helicobacter pylori* (*H. pylori*)-related peptic duodenitis. Histological normalization was checked after acid suppression and eradication therapy in both patients.

Flow cytometry

Total IELs count was similar in controls, USCD and CCD patients, whereas significant differences ($p < 0.001$) were observed in TCR $\gamma\delta^+$ and NK cells counts, when comparing controls and USCD/CCD patients. Results regarding TCR $\gamma\delta^+$ IELs and NK cells in D1 and distal duodenum are shown in Table 3. No relevant differences were observed between USCD and CCD in TCR $\gamma\delta^+$ counts, neither in D1 nor in distal duodenum. While NK cells were significantly suppressed in D1 in CCD, this phenomenon was less marked in D1 in USCD (1.4 CCD vs. 5 USCD, $p 0.04$). Since distal duodenum is not affected in USCD, NK cells counts from distal duodenum

in USCD patients were similar to those found in the control population.

Diagnosis and outcome in seronegative patients

The flow chart of patients during the diagnostic work-up is detailed in Fig. 1. Among patients with suspected USCD, there were two seronegative patients, of whom 1 had villous atrophy and the other showed Marsh II changes on bulb biopsies. Both showed HLA haplotypes, symptoms and typical celiac lymphogram in flow cytometry from bulb biopsies, all compatible with CD. Full remission, as described in the method section, was accomplished in both patients after implementation of a GFD. Interestingly, one of these patients did not express typical celiac haplotypes (DQ2 and DQ8).

As for patients with suspected CCD, there were 12 seronegative patients. Two of them had villous atrophy with

Table 3 Immunophenotypic differences in duodenal biopsies between evaluated populations. Results are expressed as mean (range).

	Controls (n = 374)	<i>p</i> [*]	CCD (n = 120)	USCD (n = 7)	<i>p</i> ^{**}
D1					
IELs	87 (76–99)	0.6	89 (74–99)	86 (68–98)	0.5
TCR $\gamma\delta$ + IELs	10 (0.6–20)	<0.001	32 (9–80)	26 (11–48)	0.3
NK cells	20 (0.1–65)	<0.001	1.4 (0–6)	5 (1.5–14)	0.04
Distal duodenum					
IELs	90 (82–99)	0.8	91 (77–99)	92 (81–97)	0.7
TCR $\gamma\delta$ + IELs	9 (0.1–18)	<0.001	29 (1.5–76)	17 (2–32)	0.5
NK cells	17 (0–74)	<0.001	3 (0–41)	14 (3–36)	<0.001

* Comparison between control and CD populations.

** Only when comparing CCD and USCD patients.

a non-celiac lymphogram. Final diagnostic work-up revealed olmesartan-associated enteropathy and autoimmune enteritis. With regards to the remaining ten patients, 5 showed villous atrophy and the other five non-specific histological findings (Marsh I–II). All ten patients had HLA haplotypes, symptoms and typical celiac lymphogram in flow cytometry, consistent with CD. All of them started a GFD with symptom resolution, along complete histological resolution and NK cells normalization after a minimum of 2 years on a GFD.

Discussion

The present study first reports data on genetic and duodenal immunophenotypic inflammatory changes in pediatric and adult patients with USCD. To begin with, there was a significant lower presence of the DQ2 haplotype in USCD. The HLA-DQ2.5 heterodimer, one variant of the DQ2 molecule, is the most permissive heterodimer for celiac disease, encoded by approximately 90% of patients with CD.¹⁴ In fact, HLA-DQ2 homozygosity has been recently shown to confer a much higher risk (25–30%) of developing early-onset CD in infants with a first-degree family member affected by the disease.¹⁵ Our findings suggest a lower frequency of the key permissive HLA-DQ2 heterodimer in USCD. Secondly, baseline NK cells suppression in USCD was significantly lower when compared to CCD patients. NK cells are a first line of immunological defence, and suppression of NK cell cytotoxic receptors represents one of the strategies to escape the host's immune system. Active inflammation in untreated CD correlates with a sharp reduction of NK cells,¹⁶ whereas NK cells count tend to normalize on duodenal biopsies after a GFD is instituted.¹⁰ Whether if a higher expression of duodenal NK cells at baseline in USCD may hint at some degree of immunotolerance, remains to be elucidated. Recently, it has been hypothesized that USCD might be an initial form of CCD.² The present study shows in USCD down-expression of HLA-DQ2 heterodimer, less tTG-IgA titration and less reduction in NK cells. Hence, it is conceivable to speculate that USCD might be an attenuated CD phenotype with incomplete inflammatory expression. It is unknown if this suggested attenuated phenotype is only present at early stages of USCD, or different forms of complete and incomplete inflammatory may

coexist. The small sample size of the present study is a clear limitation to draw any conclusion, so further bigger studies should shed light on this hypothesis.

The frequency of USCD reported in the present study is slightly lower than those previously reported,^{2,3} around 1 in 10 of CD patients. We do believe this may merely be a reflection of differences in evaluated populations or participating centers. Our adult gastroenterology department is not referral for upper endoscopy or CD study. As for children, the biopsy-sparing ESPGHAN guidelines for CD diagnosis in children, published in 2012¹⁷ and validated in 2017,¹⁸ may have modified our diagnostic picture in children. In any case, our USCD/CD diagnostic rate in the overall evaluated population reinforces the lack of usefulness of duodenal biopsies in non-selected patients.¹⁹

Both seronegativity and lower titer of antibodies were significantly higher in USCD, in accordance with previous reports.^{2,3} This lower titer may just mirror a limited level of antibodies related to limited extent of bowel involvement. Up to 70% of USCD in our series exhibited previous normal duodenal biopsies and up to 42% of USCD patients in our series had a previous diagnosis of potential CD (normal histology with symptoms and positive serology).^{1,9} While progression to villous atrophy has been recently described in almost half patients with potential CD,²⁰ we do humbly speculate that either poor biopsy sampling combined with lack of inclusion of D1 biopsies was the most likely reason for misdiagnosis in this subset of our patients.

Seronegative CCD patients (8%) included in the present study is in full accordance with previous reports.^{13,21} Inclusion of seronegative patients without villous atrophy might be more controversial, but typical symptoms, HLA haplotypes and celiac lymphogram were present in all of them. The diagnostic supporting role of flow cytometry of this difficult-to-diagnose patients has been recently confirmed in systematic reviews and meta-analyses⁸ and updated iterations of diagnostic guidelines.^{1,9} Additionally, these patients were carefully followed-up with documented resolution of clinic, histologic and flow cytometry findings on a GFD. All of our controversial CCD and USCD patients achieved complete histological remission after a minimum of 2 years on a GFD. These findings contrast with those shown by a recent prospective multicenter study conducted in adults, in which

up to 50% may have persistent villous atrophy after 2 years on a GFD.²² Some potential reasons for this discrepancy may be less severe lesions and longer GFD duration in our study. On another level, it may be reasonably questionable whether a strict GFD might be required for USCD patients, since it seems to be an early milder phenotype associated with fewer micronutrient deficiencies.^{2,3} Symptomatic, histologic and immunological improvement observed in the present study for seronegative USCD patients, similar to that found in patients with seronegative CCD, appear to suggest that the immune cascade was switched off in both cases and may fully justify a strict GFD for USCD.

The present study has several drawbacks, mainly recruitment from a single center and a small sample size, specially in the USCD group. The lack of dietitian or gluten immunogenic peptide tests to monitor adherence to a GFD in patients undergoing follow-up endoscopy are also potential limitations. It could have been also useful to perform gluten provocation tests in order to reproduce symptoms and/or histological/immunological features in difficult-to-diagnose patients (e.g. seronegative coeliac disease or HLA-DQ2-DQ8 negative cases).^{23,24} Strengths to the study may include evaluation of HLA haplotypes and immunophenotypic data from flow cytometry, separating D1 and distal duodenum information, in USCD and CCD patients, as well as careful follow-up of seronegative patients, including flow cytometry data.

In conclusion, USCD was found in 5.5% of pediatric and adult patients in our series, supporting the importance of optimal D1 sampling in CD histologic diagnostic work-up. Novel findings for USCD include a lower frequency of HLA-DQ2 and a different cytometry pattern, with a limited down-expression of NK cells. These data suggest that USCD may be an early form of CD with an attenuated inflammatory phenotype.

Authors' contribution

P M-R and D M-H: inclusion of patients, data acquisition/interpretation, drafting of the article, critical revision; HC F-N, PL G-C, A I-M, P B-G: inclusion of patients, critical revision; N F-G: histopathologic analysis, critical revision; L F-P, C C-H: laboratory work, critical revision; J M-I: study design, inclusion of patients, data interpretation, drafting of the article, critical revision

Funding sources

The authors did not receive any fundings for the present study.

Conflict of interest

The authors declare no conflict of interest regarding its content.

Acknowledgements

We are grateful to the Department of Immunology at Hospital Universitario de Badajoz, Extremadura, Spain, who were responsible for laboratory work related to HLA haplotypes.

References

1. Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *Unit Eur Gastroenterol J*. 2019;7:583–613.
2. Mooney PD, Kurien M, Evans KE, Rosario E, Cross SS, Vergani P, et al. Clinical and immunologic features of ultra-short celiac disease. *Gastroenterology*. 2016;150:1125–34.
3. Doyev R, Cohen S, Ben-Tov A, Weintraub Y, Amir A, Galai T, et al. Ultra-short celiac disease is a distinct and milder phenotype of the disease in children. *Dig Dis Sci*. 2019;64:167–72.
4. Järvinen TT, Kaukinen K, Laurila K, Kyrönpalo S, Rasmussen M, Mäki M, et al. Intraepithelial lymphocytes in celiac disease. *Am J Gastroenterol*. 2003;98:1332–7.
5. Calleja S, Vivas S, Santiuste M, Arias L, Hernando M, Nistal E, et al. Dynamics of non-conventional intraepithelial lymphocytes—NK, NKT, and $\gamma\delta$ T—In celiac disease: relationship with age, diet, and histopathology. *Dig Dis Sci*. 2011;56:2042–9.
6. Nijeboer P, van Gils T, Reijm M, Ooijselaar R, Lissenberg-Witte BI, Bontkes HJ, et al. Gamma-delta T lymphocytes in the diagnostic approach of coeliac disease. *J Clin Gastroenterol*. 2019;53:e208–13.
7. Fernández-Bañares F, Crespo L, Núñez C, López-Palacios N, Tristán E, Vivas S, et al. Gamma delta+ intraepithelial lymphocytes and coeliac lymphogram in a diagnostic approach to coeliac disease in patients with seronegative villous atrophy. *Aliment Pharmacol Ther*. 2020;51:699–705.
8. Fernández-Bañares F, Carrasco A, Martín A, Esteve M. Systematic review and meta-analysis: accuracy of both gamma delta+ intraepithelial lymphocytes and coeliac lymphogram evaluated by flow cytometry for coeliac disease diagnosis. *Nutrients*. 2019;11:1992.
9. Husby S, Koletzko S, Korponay-Szabó I, Kurppa K, Mearin ML, Ribes-Koninckx C, et al. European society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing coeliac disease 2020. *J Pediatr Gastroenterol Nutr*. 2020;70:141–56.
10. Eiras P, Roldán E, Camarero C, Olivares F, Bootello A, Roy G. Flow cytometry description of a novel CD3+/CD7+ intraepithelial lymphocyte subset in human duodenal biopsies: potential diagnostic value in coeliac disease. *Cytometry*. 1998;34:95–102.
11. Aziz I, Peerally MF, Barnes JH, Kandasamy V, Whiteley JC, Partridge D, et al. The clinical and phenotypic assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). *Gut*. 2017;66:1563–72.
12. Catassi C, Fasano A. Celiac disease diagnosis: simple rules are better than complicated algorithms. *Am J Med*. 2010;123:691–3.
13. Leonard MM, Lebwohl B, Rubio-Tapia A, Biagi F. AGA clinical practice update on the evaluation and management of seronegative enteropathies: expert review. *Gastroenterology*. 2021;160:437–44.
14. Brown NK, Guandalini S, Semrad C, Kupfer SS. A clinician's guide to celiac disease HLA genetics. *Am J Gastroenterol*. 2019;114:1587–92.
15. Liu E, Lee HS, Aronsson CA, Hagopian WA, Koletzko S, Rewers MJ, et al. Risk of pediatric celiac disease according to HLA haplotype and country. *N Engl J Med*. 2014;371:42–9.
16. Marafini I, Monteleone I, Di Fusco D, Sedda S, Cupi ML, Fina D, et al. Celiac disease-related inflammation is marked by reduction of Nkp44/Nkp46-double positive natural killer cells. *PLOS ONE*. 2016;11:e0155103.
17. Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, et al. European society for pediatric gastroenterology,

- hepatology, and nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr.* 2012;54:136–60.
18. Werkstetter KJ, Korponay-Szabó IR, Popp A, Villanacci V, Salemme M, Heilig G, et al. Accuracy in diagnosis of celiac disease without biopsies in clinical practice. *Gastroenterology.* 2017;153:924–35.
 19. Stoven SA, Choung RS, Rubio-Tapia A, Absah I, Lam-Himlin DM, Harris LA, et al. Analysis of biopsies from duodenal bulbs of all endoscopy patients increases detection of abnormalities but has a minimal effect on diagnosis of celiac disease. *Clin Gastroenterol Hepatol.* 2016;14:1582–8.
 20. Auricchio R, Mandile R, Del Vecchio MR, Scapaticci S, Galatola M, Maglio M, et al. Progression of celiac disease in children with antibodies against tissue transglutaminase and normal duodenal architecture. *Gastroenterology.* 2019;157:413–20.
 21. Volta U, Caio G, Boschetti E, Giancola F, Rhoden KJ, Ruggeri E, et al. Seronegative celiac disease: shedding light on an obscure clinical entity. *Dig Liver Dis.* 2016;48:1018–22.
 22. Fernández-Bañares F, Beltrán B, Salas A, Comino I, Ballester-Clau R, Ferrer C, et al. Persistent villous atrophy in de novo adult patients with celiac disease and strict control of gluten-free diet adherence: a multicenter prospective study (CADER Study). *Am J Gastroenterol.* 2021;116:1036–43.
 23. López-Palacios N, Pascual V, Castaño M, Bodas A, Fernández-Prieto M, Espino-Paisán L, et al. Evaluation of T cells in blood after a short gluten challenge for coeliac disease diagnosis. *Dig Liver Dis.* 2018;50:1183–8.
 24. Nuñez C, Fernandez-Bañares F. Some considerations about $\gamma\delta$ and CD8⁺ T-cell responses in blood after gluten challenge in treated celiac disease. *Mucosal Immunol.* 2021;14:1214–5.